{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T19:29:58Z","timestamp":1786476598564,"version":"build-2736575974"},"reference-count":99,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T00:00:00Z","timestamp":1786406400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T00:00:00Z","timestamp":1786406400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Differ"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Metastatic colorectal cancer (mCRC) is one of the deadliest cancers with very poor response to immune checkpoint blockade (ICB). Standard therapies employ chemotherapy combined with epidermal growth factor receptor (EGFR) blocking antibodies, which are only effective in a fraction of patients with RAS\/RAF wild-type tumours. We have previously shown that EGFR deletion in myeloid cells of CRC, rather than in the cancer cells themselves, reduces tumour growth. Here, we investigate to which extent EGFR blockade in myeloid cells increases anti-tumour immunity, thus sensitising CRC to ICB. Using a syngeneic preclinical CRC liver metastasis model based on the transplantation of murine RAS mutant CRC organoids into mice lacking EGFR in myeloid cells, we observe a reduction in metastasis development accompanied by increased intratumoural T-cell infiltration. Importantly, we demonstrate that EGFR deletion reduces the capacity of granulocytic myeloid-derived suppressor cells (G-MDSCs) to suppress CD4\n                    <jats:sup>+<\/jats:sup>\n                    T-cell proliferation. RNA-seq analysis of sorted MDSCs and T-cells uncovered an EGFR-dependent signature involved in immunosuppression, which in proficient-mismatch-repair (pMMR) CRC patients is associated with worse overall survival. Therapeutically, lifting immunosuppression by EGFR deletion in myeloid cells sensitised tumours to anti-PD-L1 treatment, thus preventing liver metastasis development. These results imply that anti-EGFR therapies combined with ICB might be successful in preventing metastasis of RAS mutated CRC with high infiltration of suppressive EGFR\n                    <jats:sup>+<\/jats:sup>\n                    myeloid cells.\n                  <\/jats:p>","DOI":"10.1038\/s41418-026-01828-0","type":"journal-article","created":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T17:47:06Z","timestamp":1786470426000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Absence of EGFR signalling in granulocytic cells relieves immunosuppression sensitising CRC metastases to immune checkpoint therapy"],"prefix":"10.1038","author":[{"given":"Veronica","family":"Moreno-Viedma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emi","family":"Adachi-Fernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana","family":"Krauss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Mohr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernadette","family":"Blauensteiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorun","family":"Buresch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilyana","family":"Mireva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleftherios","family":"Kokkinogenis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Filipits","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Holcmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1522-3496","authenticated-orcid":false,"given":"Daniele V. F.","family":"Tauriello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2422-0326","authenticated-orcid":false,"given":"Eduard","family":"Batlle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6129-5613","authenticated-orcid":false,"given":"Maria","family":"Sibilia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,11]]},"reference":[{"key":"1828_CR1","first-page":"1","volume":"1","author":"EJ Kuipers","year":"2015","unstructured":"Kuipers EJ, Grady WM, Lieberman D, Seufferlein T, Sung JJ, Boelens PG, et al. Colorectal cancer. Nat Rev Dis Prim. 2015;1:1\u201325.","journal-title":"Nat Rev Dis Prim"},{"key":"1828_CR2","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209\u201349.","journal-title":"CA Cancer J Clin"},{"key":"1828_CR3","first-page":"1","volume":"66","author":"ACS","year":"2020","unstructured":"ACS. Colorectal cancer facts and figures 2020\u20132. Am Cancer Soc. 2020;66:1\u201341.","journal-title":"Am Cancer Soc"},{"key":"1828_CR4","first-page":"46","volume":"14","author":"JJ Lee","year":"2016","unstructured":"Lee JJ, Sun W. Options for second-line treatment in metastatic colorectal cancer. Clin Adv Hematol Oncol. 2016;14:46\u201354.","journal-title":"Clin Adv Hematol Oncol"},{"key":"1828_CR5","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1200\/EDBK_175679","volume":"37","author":"CE Atreya","year":"2017","unstructured":"Atreya CE, Rona Y, Chu E. Systemic therapy for metastatic colorectal cancer: from current standards to future molecular targeted approaches. Am Soc Clin Oncol Educ Book. 2017;37:246\u201356.","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"1828_CR6","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1001\/jama.2021.0106","volume":"325","author":"LH Biller","year":"2021","unstructured":"Biller LH, Schrag D. Diagnosis and treatment of metastatic colorectal cancer: a review. JAMA. 2021;325:669\u201385.","journal-title":"JAMA"},{"key":"1828_CR7","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1093\/annonc\/mdu378","volume":"26","author":"MJ Sorich","year":"2015","unstructured":"Sorich MJ, Wiese MD, Rowland A, Kichenadasse G, McKinnon RA, Karapetis CS. Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials. Ann Oncol. 2015;26:13\u201321.","journal-title":"Ann Oncol"},{"key":"1828_CR8","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1200\/JCO.2007.14.7116","volume":"26","author":"RG Amado","year":"2008","unstructured":"Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol. 2008;26:1626\u201334.","journal-title":"J Clin Oncol"},{"key":"1828_CR9","doi-asserted-by":"publisher","unstructured":"Herpers B, Eppink B, James MI, Cortina C, Ca\u00f1ellas-socias A, Boj SF, et al. Functional patient-derived organoid screenings identify MCLA-158 as a therapeutic EGFR \u00d7 LGR5 bispecific antibody with efficacy in epithelial tumors. 2022. Nat Cancer. https:\/\/doi.org\/10.1038\/s43018-022-00359-0.","DOI":"10.1038\/s43018-022-00359-0"},{"key":"1828_CR10","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1111\/j.1432-0436.2007.00238.x","volume":"75","author":"M Sibilia","year":"2007","unstructured":"Sibilia M, Kroismayr R, Lichtenberger BM, Natarajan A, Hecking M, Holcmann M. The epidermal growth factor receptor: from development to tumorigenesis. Differentiation. 2007;75:770\u201387.","journal-title":"Differentiation"},{"key":"1828_CR11","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.ccr.2012.08.001","volume":"22","author":"C Navas","year":"2012","unstructured":"Navas C, Hern\u00e1ndez-Porras I, Schuhmacher AJ, Sibilia M, Guerra C, Barbacid M. EGF receptor signaling is essential for K-Ras oncogene-driven pancreatic ductal adenocarcinoma. Cancer Cell. 2012;22:318\u201330.","journal-title":"Cancer Cell"},{"key":"1828_CR12","doi-asserted-by":"crossref","unstructured":"Ardito CM, Gr\u00fcner BM, Takeuchi KK, Lubeseder- C, Teichmann N, Mazur PK, et al. EGF receptor is required for KRAS-induced pancreatic tumorigenesis. Cancer Cell. 2013;22:304\u201317.","DOI":"10.1016\/j.ccr.2012.07.024"},{"key":"1828_CR13","doi-asserted-by":"crossref","unstructured":"Moll HP, Pranz K, Musteanu M, Grabner B, Hruschka N, Mohrherr J, et al. Afatinib restrains K-RAS-driven lung tumorigenesis. Sci Transl Med. 2018;10:eaao23012018.","DOI":"10.1126\/scitranslmed.aao2301"},{"key":"1828_CR14","doi-asserted-by":"publisher","unstructured":"Linder M, Glitzner E, Srivatsa S, Bakiri L, Matsuoka K, Shahrouzi P, et al. EGFR is required for FOS-dependent bone tumor development via RSK2\/CREB signaling. EMBO Mol Med. 2018. https:\/\/doi.org\/10.15252\/emmm.201809408.","DOI":"10.15252\/emmm.201809408"},{"key":"1828_CR15","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1056\/NEJMoa033025","volume":"351","author":"D Cunningham","year":"2004","unstructured":"Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004;351:337\u201345.","journal-title":"N Engl J Med"},{"key":"1828_CR16","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1038\/ncb3031","volume":"16","author":"H Lanaya","year":"2014","unstructured":"Lanaya H, Natarajan A, Komposch K, Li L, Amberg N, Chen L, et al. EGFR has a tumour-promoting role in liver macrophages during hepatocellular carcinoma formation. Nat Cell Biol. 2014;16:972\u201381.","journal-title":"Nat Cell Biol"},{"key":"1828_CR17","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1053\/j.gastro.2017.03.053","volume":"153","author":"S Srivatsa","year":"2017","unstructured":"Srivatsa S, Paul MC, Cardone C, Holcmann M, Amberg N, Pathria P, et al. EGFR in tumor-associated myeloid cells promotes development of colorectal cancer in mice and associates with outcomes of patients. Gastroenterology. 2017;153:178\u201390.e10.","journal-title":"Gastroenterology"},{"key":"1828_CR18","doi-asserted-by":"publisher","first-page":"3807","DOI":"10.1038\/onc.2017.23","volume":"36","author":"DM Hardbower","year":"2017","unstructured":"Hardbower DM, Coburn LA, Asim M, Singh K, Sierra JC, Barry DP, et al. EGFR-mediated macrophage activation promotes colitis-associated tumorigenesis. Oncogene. 2017;36:3807\u201319.","journal-title":"Oncogene"},{"key":"1828_CR19","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1038\/s41575-019-0126-x","volume":"16","author":"K Ganesh","year":"2019","unstructured":"Ganesh K, Stadler ZK, Cercek A, Mendelsohn RB, Shia J, Segal NH, et al. Immunotherapy in colorectal cancer: rationale, challenges and potential. Nat Rev Gastroenterol Hepatol. 2019;16:361\u201375.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"1828_CR20","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1038\/s41416-019-0599-y","volume":"121","author":"IH Sahin","year":"2019","unstructured":"Sahin IH, Akce M, Alese O, Shaib W, Lesinski GB, El-Rayes B, et al. Immune checkpoint inhibitors for the treatment of MSI-H\/MMR-D colorectal cancer and a perspective on resistance mechanisms. Br J Cancer. 2019;121:809\u201318.","journal-title":"Br J Cancer"},{"key":"1828_CR21","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/j.ccell.2019.02.008","volume":"35","author":"W Liao","year":"2019","unstructured":"Liao W, Overman MJ, Boutin AT, Shang X, Zhao D, Dey P, et al. KRAS-IRF2 axis drives immune suppression and immune therapy resistance in colorectal cancer. Cancer Cell. 2019;35:559\u201372.e7.","journal-title":"Cancer Cell"},{"key":"1828_CR22","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1016\/j.ccr.2012.04.024","volume":"21","author":"Y Pylayeva-Gupta","year":"2012","unstructured":"Pylayeva-Gupta Y, Lee KE, Hajdu CH, Miller G, Bar-Sagi D. Oncogenic Kras-induced GM-CSF production promotes the development of pancreatic neoplasia. Cancer Cell. 2012;21:836\u201347.","journal-title":"Cancer Cell"},{"key":"1828_CR23","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1038\/nrc3581","volume":"13","author":"JE Talmadge","year":"2013","unstructured":"Talmadge JE, Gabrilovich DI. History of myeloid-derived suppressor cells. Nat Rev Cancer. 2013;13:739\u201352.","journal-title":"Nat Rev Cancer"},{"key":"1828_CR24","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1038\/nri2506","volume":"9","author":"DI Gabrilovich","year":"2009","unstructured":"Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol. 2009;9:162\u201374.","journal-title":"Nat Rev Immunol"},{"key":"1828_CR25","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1038\/s41577-020-00490-y","volume":"21","author":"F Veglia","year":"2021","unstructured":"Veglia F, Sanseviero E, Gabrilovich DI. Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity. Nat Rev Immunol. 2021;21:485\u201398.","journal-title":"Nat Rev Immunol"},{"key":"1828_CR26","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1084\/jem.20050715","volume":"202","author":"PC Rodriguez","year":"2005","unstructured":"Rodriguez PC, Hernandez CP, Quiceno D, Dubinett SM, Zabaleta J, Ochoa JB, et al. Arginase I in myeloid suppressor cells is induced by COX-2 in lung carcinoma. J Exp Med. 2005;202:931\u20139.","journal-title":"J Exp Med"},{"key":"1828_CR27","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/nri3175","volume":"12","author":"DI Gabrilovich","year":"2012","unstructured":"Gabrilovich DI, Ostrand-Rosenberg S, Bronte V. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol. 2012;12:253\u201368.","journal-title":"Nat Rev Immunol"},{"key":"1828_CR28","doi-asserted-by":"publisher","first-page":"2693","DOI":"10.1158\/2159-8290.CD-21-0764","volume":"11","author":"A Grover","year":"2021","unstructured":"Grover A, Sanseviero E, Timosenko E, Gabrilovich DI. Myeloid-derived suppressor cells: a propitious road to clinic. Cancer Discov. 2021;11:2693\u2013706.","journal-title":"Cancer Discov"},{"key":"1828_CR29","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/s41591-018-0014-x","volume":"24","author":"M Binnewies","year":"2018","unstructured":"Binnewies M, Roberts EW, Kersten K, Chan V, Fearon DF, Merad M, et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med. 2018;24:541\u201350.","journal-title":"Nat Med"},{"key":"1828_CR30","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1023\/A:1008942828960","volume":"8","author":"BE Clausen","year":"1999","unstructured":"Clausen BE, Burkhardt C, Reith W, Renkawitz R, F\u00f6rster I. Conditional gene targeting in macrophages and granulocytes using LysMcre mice. Transgenic Res. 1999;8:265\u201377.","journal-title":"Transgenic Res"},{"key":"1828_CR31","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1038\/nature25492","volume":"554","author":"DVF Tauriello","year":"2018","unstructured":"Tauriello DVF, Palomo-Ponce S, Stork D, Berenguer-Llergo A, Badia-Ramentol J, Iglesias M, et al. TGF\u03b2 drives immune evasion in genetically reconstituted colon cancer metastasis. Nature. 2018;554:538\u201343.","journal-title":"Nature"},{"key":"1828_CR32","doi-asserted-by":"publisher","first-page":"e1364828","DOI":"10.1080\/2162402X.2017.1364828","volume":"7","author":"S Simon","year":"2017","unstructured":"Simon S, Labarriere N. PD-1 expression on tumor-specific T cells: friend or foe for immunotherapy?. Oncoimmunology. 2017;7:e1364828.","journal-title":"Oncoimmunology"},{"key":"1828_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/ncomms14572","volume":"8","author":"J Lau","year":"2017","unstructured":"Lau J, Cheung J, Navarro A, Lianoglou S, Haley B, Totpal K, et al. Tumour and host cell PD-L1 is required to mediate suppression of anti-tumour immunity in mice. Nat Commun. 2017;8:1\u201311.","journal-title":"Nat Commun"},{"key":"1828_CR34","doi-asserted-by":"publisher","first-page":"508","DOI":"10.4161\/cib.3.6.13495","volume":"3","author":"BJG Baaten","year":"2010","unstructured":"Baaten BJG, Li CR, Bradley LM. Multifaceted regulation of T cells by CD44. Commun Integr Biol. 2010;3:508\u201312.","journal-title":"Commun Integr Biol"},{"key":"1828_CR35","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1002\/eji.201646837","volume":"47","author":"D Cibri\u00e1n","year":"2017","unstructured":"Cibri\u00e1n D, S\u00e1nchez-Madrid F. CD69: from activation marker to metabolic gatekeeper. Eur J Immunol. 2017;47:946.","journal-title":"Eur J Immunol"},{"key":"1828_CR36","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1093\/intimm\/dxy050","volume":"30","author":"Y Mita","year":"2018","unstructured":"Mita Y. Crucial role of CD69 in anti-tumor immunity through regulating the exhaustion of tumor-infiltrating T cells. Int Immunol. 2018;30:559\u201367.","journal-title":"Int Immunol"},{"key":"1828_CR37","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1111\/j.1365-2567.2011.03446.x","volume":"133","author":"B Fu","year":"2011","unstructured":"Fu B, Wang F, Sun R, Ling B, Tian Z, Wei H. CD11b and CD27 reflect distinct population and functional specialization in human natural killer cells. Immunology. 2011;133:350.","journal-title":"Immunology"},{"key":"1828_CR38","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1061959","volume":"13","author":"E Bourayou","year":"2022","unstructured":"Bourayou E, Golub R. Inflammatory-driven NK cell maturation and its impact on pathology. Front Immunol. 2022;13:1061959.","journal-title":"Front Immunol"},{"key":"1828_CR39","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1007\/s00262-022-03337-8","volume":"72","author":"MA Al-Mterin","year":"2023","unstructured":"Al-Mterin MA, Murshed K, Elkord E. PD-1 expression, among other immune checkpoints, on tumor-infiltrating NK and NKT cells is associated with longer disease-free survival in treatment-na\u00efve CRC patients. Cancer Immunol Immunother. 2023;72:1933\u20139.","journal-title":"Cancer Immunol Immunother"},{"key":"1828_CR40","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/nri1001","volume":"3","author":"G Trinchieri","year":"2003","unstructured":"Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol. 2003;3:133\u201346.","journal-title":"Nat Rev Immunol"},{"key":"1828_CR41","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1158\/2326-6066.CIR-17-0341","volume":"5","author":"D Mittal","year":"2017","unstructured":"Mittal D, Vijayan D, Putz EM, Aguilera AR, Markey KA, Straube J, et al. Interleukin-12 from CD103+ Batf3-dependent dendritic cells required for NK-cell suppression of metastasis. Cancer Immunol Res. 2017;5:1098\u2013108.","journal-title":"Cancer Immunol Res"},{"key":"1828_CR42","doi-asserted-by":"publisher","unstructured":"Wiedemann GM, Knott MML, Vetter VK, Rapp M, Haubner S, Fesseler J, et al. Cancer cell-derived IL-1\u03b1 induces CCL22 and the recruitment of regulatory T cells. Oncoimmunology. 2016. https:\/\/doi.org\/10.1080\/2162402X.2016.1175794.","DOI":"10.1080\/2162402X.2016.1175794"},{"key":"1828_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s42003-020-01441-y","volume":"3","author":"MM Tu","year":"2020","unstructured":"Tu MM, Abdel-Hafiz HA, Jones RT, Jean A, Hoff KJ, Duex JE, et al. Inhibition of the CCL2 receptor, CCR2, enhances tumor response to immune checkpoint therapy. Commun Biol. 2020;3:1\u201312.","journal-title":"Commun Biol"},{"key":"1828_CR44","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/s41417-021-00303-x","volume":"29","author":"K Kohli","year":"2022","unstructured":"Kohli K, Pillarisetty VG, Kim TS. Key chemokines direct migration of immune cells in solid tumors. Cancer Gene Ther. 2022;29:10\u201321.","journal-title":"Cancer Gene Ther"},{"key":"1828_CR45","doi-asserted-by":"publisher","first-page":"5514","DOI":"10.4049\/jimmunol.179.8.5514","volume":"179","author":"A Bafica","year":"2007","unstructured":"Bafica A, Feng CG, Santiago HC, Aliberti J, Cheever A, Thomas KE, et al. The IFN-inducible GTPase LRG47 (Irgm1) negatively regulates TLR4-triggered proinflammatory cytokine production and prevents endotoxemia. J Immunol. 2007;179:5514\u201322.","journal-title":"J Immunol"},{"key":"1828_CR46","doi-asserted-by":"publisher","first-page":"1190333","DOI":"10.3389\/fimmu.2023.1190333","volume":"14","author":"J Han","year":"2023","unstructured":"Han J, Wu M, Liu Z. Dysregulation in IFN-\u03b3 signaling and response: the barricade to tumor immunotherapy. Front Immunol. 2023;14:1190333.","journal-title":"Front Immunol"},{"key":"1828_CR47","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1038\/s41586-020-2422-6","volume":"583","author":"T Zhou","year":"2020","unstructured":"Zhou T, Damsky W, Weizman OEL, McGeary MK, Hartmann KP, Rosen CE, et al. IL-18BP is a secreted immune checkpoint and barrier to IL-18 immunotherapy. Nature. 2020;583:609\u201314.","journal-title":"Nature"},{"key":"1828_CR48","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1039993","volume":"12","author":"RM Raghani","year":"2022","unstructured":"Raghani RM, Ma JA, Zhang Y, Orbach SM, Wang J, Zeinali M, et al. Myeloid cell reprogramming alleviates immunosuppression and promotes clearance of metastatic lesions. Front Oncol. 2022;12:1039993.","journal-title":"Front Oncol"},{"key":"1828_CR49","doi-asserted-by":"publisher","first-page":"20399","DOI":"10.1074\/jbc.271.34.20399","volume":"271","author":"GA Taylor","year":"1996","unstructured":"Taylor GA, Jeffers M, Largaespada DA, Jenkins NA, Copeland NG, Vande Woude GF. Identification of a novel GTPase, the inducibly expressed GTPase, that accumulates in response to interferon \u03b3. J Biol Chem. 1996;271:20399\u2013405.","journal-title":"J Biol Chem"},{"key":"1828_CR50","doi-asserted-by":"publisher","first-page":"819","DOI":"10.3389\/fimmu.2019.00819","volume":"10","author":"G Upadhyay","year":"2019","unstructured":"Upadhyay G. Emerging role of lymphocyte antigen-6 family of genes in cancer and immune cells. Front Immunol. 2019;10:819.","journal-title":"Front Immunol"},{"key":"1828_CR51","doi-asserted-by":"crossref","unstructured":"Cevik SI, Keskin N, Belkaya S, Ozlu MI, Deniz E. Cd81 interacts with the T cell receptor to suppress signaling. PLoS ONE. 2012;7:e50396.","DOI":"10.1371\/journal.pone.0050396"},{"key":"1828_CR52","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.celrep.2016.12.019","volume":"18","author":"P Charoentong","year":"2017","unstructured":"Charoentong P, Finotello F, Angelova M, Mayer C, Efremova M, Rieder D, et al. Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade. Cell Rep. 2017;18:248\u201362.","journal-title":"Cell Rep"},{"key":"1828_CR53","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2019.02243","volume":"10","author":"M Huang","year":"2019","unstructured":"Huang M, Wu R, Chen L, Peng Q, Li S, Zhang Y, et al. S100A9 regulates MDSCs-mediated immune suppression via the RAGE and TLR4 signaling pathways in colorectal carcinoma. Front Immunol. 2019;10:1\u201313.","journal-title":"Front Immunol"},{"key":"1828_CR54","doi-asserted-by":"publisher","first-page":"6562","DOI":"10.4049\/jimmunol.0803831","volume":"182","author":"S Mandruzzato","year":"2009","unstructured":"Mandruzzato S, Solito S, Falisi E, Francescato S, Chiarion-Sileni V, Mocellin S, et al. IL4R\u03b1+ myeloid-derived suppressor cell expansion in cancer patients. J Immunol. 2009;182:6562\u20138.","journal-title":"J Immunol"},{"key":"1828_CR55","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/nri1995","volume":"7","author":"H Yu","year":"2007","unstructured":"Yu H, Kortylewski M, Pardoll D. Crosstalk between cancer and immune cells: Role of STAT3 in the tumour microenvironment. Nat Rev Immunol. 2007;7:41\u201351.","journal-title":"Nat Rev Immunol"},{"key":"1828_CR56","doi-asserted-by":"publisher","first-page":"619253","DOI":"10.3389\/fimmu.2020.619253","volume":"11","author":"N Fultang","year":"2021","unstructured":"Fultang N, Li X, Li T, Chen YH. Myeloid-derived suppressor cell differentiation in cancer: transcriptional regulators and enhanceosome-mediated mechanisms. Front Immunol. 2021;11:619253.","journal-title":"Front Immunol"},{"key":"1828_CR57","doi-asserted-by":"publisher","first-page":"58.06","DOI":"10.4049\/jimmunol.206.Supp.58.06","volume":"206","author":"M Shourian","year":"2021","unstructured":"Shourian M, Bourdin B, Decaluwe H. Inhibition of JAK\/STAT signaling sustain stem-like exhausted CD8\u2009+\u2009T lymphocytes with enhanced antitumor effects. J Immunol. 2021;206:58.06\u201358.06.","journal-title":"J Immunol"},{"key":"1828_CR58","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.cell.2020.03.048","volume":"181","author":"L Zhang","year":"2020","unstructured":"Zhang L, Li Z, Skrzypczynska KM, Fang Q, Zhang W, O\u2019Brien SA, et al. Single-cell analyses inform mechanisms of myeloid-targeted therapies in colon cancer. Cell. 2020;181:442\u201359.e29.","journal-title":"Cell"},{"key":"1828_CR59","doi-asserted-by":"publisher","unstructured":"Wang J, Zhu N, Su X, Gao Y, Yang R. Novel tumor-associated macrophage populations and subpopulations by single cell RNA sequencing. Front Immunol. 2024. https:\/\/doi.org\/10.3389\/FIMMU.2023.1264774.","DOI":"10.3389\/FIMMU.2023.1264774"},{"key":"1828_CR60","doi-asserted-by":"publisher","unstructured":"Bronte V, Brandau S, Chen S, Colombo MP, Frey AB, Greten TF, et al. Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards. Nat Commun. https:\/\/doi.org\/10.1038\/ncomms12150.","DOI":"10.1038\/ncomms12150"},{"key":"1828_CR61","doi-asserted-by":"publisher","first-page":"635","DOI":"10.3109\/08820139.2012.695417","volume":"41","author":"N Obermajer","year":"2012","unstructured":"Obermajer N, Wong JL, Edwards RP, Odunsi K, Moysich K, Kalinski P. PGE2-driven induction and maintenance of cancer-associated myeloid-derived suppressor cells. Immunol Invest. 2012;41:635\u201357.","journal-title":"Immunol Invest"},{"key":"1828_CR62","doi-asserted-by":"publisher","first-page":"7843","DOI":"10.18632\/oncotarget.2279","volume":"5","author":"T Liechtenstein","year":"2014","unstructured":"Liechtenstein T, Perez-Janices N, Gato M, Caliendo F, Kochan G, Blanco-Luquin I, et al. A highly efficient tumor-infiltrating MDSC differentiation system for discovery of anti-neoplastic targets, which circumvents the need for tumor establishment in mice. Oncotarget. 2014;5:7843\u201357.","journal-title":"Oncotarget"},{"key":"1828_CR63","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1182\/blood-2007-04-086835","volume":"111","author":"PY Pan","year":"2008","unstructured":"Pan PY, Wang GX, Yin B, Ozao J, Ku T, Divino CM, et al. Reversion of immune tolerance in advanced malignancy: modulation of myeloid-derived suppressor cell development by blockade of stem-cell factor function. Blood. 2008;111:219\u201328.","journal-title":"Blood"},{"key":"1828_CR64","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.cellimm.2006.07.007","volume":"241","author":"CA Skilbeck","year":"2006","unstructured":"Skilbeck CA, Lu X, Sheikh S, Savage COS, Nash GB. Capture of flowing human neutrophils by immobilised immunoglobulin: roles of Fc-receptors CD16 and CD32. Cell Immunol. 2006;241:26\u201331.","journal-title":"Cell Immunol"},{"key":"1828_CR65","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1182\/blood-2004-12-4942","volume":"106","author":"L Yang","year":"2005","unstructured":"Yang L, Froio RM, Sciuto TE, Dvorak AM, Alon R, Luscinskas FW. ICAM-1 regulates neutrophil adhesion and transcellular migration of TNF-\u03b1-activated vascular endothelium under flow. Blood. 2005;106:584\u201392.","journal-title":"Blood"},{"key":"1828_CR66","doi-asserted-by":"publisher","first-page":"3889","DOI":"10.4049\/jimmunol.0903136","volume":"184","author":"B Bayat","year":"2010","unstructured":"Bayat B, Werth S, Sachs UJH, Newman DK, Newman PJ, Santoso S. Neutrophil transmigration mediated by the neutrophil-specific antigen CD177 is influenced by the endothelial S536N dimorphism of platelet endothelial cell adhesion molecule-1. J Immunol. 2010;184:3889\u201396.","journal-title":"J Immunol"},{"key":"1828_CR67","doi-asserted-by":"publisher","first-page":"6807","DOI":"10.1158\/0008-5472.CAN-05-3755","volume":"66","author":"R Yang","year":"2006","unstructured":"Yang R, Cai Z, Zhang Y, Yutzy IVWH, Roby KF, Roden RBS. CD80 in immune suppression by mouse ovarian carcinoma-associated Gr-1\u2009+\u2009CD11b + myeloid cells. Cancer Res. 2006;66:6807\u201315.","journal-title":"Cancer Res"},{"key":"1828_CR68","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.138581","volume":"5","author":"A Ugolini","year":"2020","unstructured":"Ugolini A, Tyurin VA, Tyurina YY, Tcyganov EN, Donthireddy L, Kagan VE, et al. Polymorphonuclear myeloid-derived suppressor cells limit antigen crosspresentation by dendritic cells in cancer. JCI Insight. 2020;5:e138581.","journal-title":"JCI Insight"},{"key":"1828_CR69","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1158\/0008-5472.CAN-08-1921","volume":"69","author":"PC Rodriguez","year":"2009","unstructured":"Rodriguez PC, Ernstoff MS, Hernandez C, Atkins M, Zabaleta J, Sierra R, et al. Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes. Cancer Res. 2009;69:1553\u201360.","journal-title":"Cancer Res"},{"key":"1828_CR70","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","volume":"375","author":"M Reck","year":"2016","unstructured":"Reck M, Rodr\u00edguez-Abreu D, Robinson AG, Hui R, Cs\u0151szi T, F\u00fcl\u00f6p A, et al. Pembrolizumab versus chemotherapy for PD-L1\u2013positive non\u2013small-cell lung cancer. N Engl J Med. 2016;375:1823\u201333.","journal-title":"N Engl J Med"},{"key":"1828_CR71","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1186\/s40425-019-0768-9","volume":"7","author":"AA Davis","year":"2019","unstructured":"Davis AA, Patel VG. The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors. J Immunother Cancer. 2019;7:278.","journal-title":"J Immunother Cancer"},{"key":"1828_CR72","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1189\/jlb.0112048","volume":"92","author":"RN Ramos","year":"2012","unstructured":"Ramos RN, Chin LS, dos Santos APSA, Bergami-Santos PC, Laginha F, Barbuto JAM. Monocyte-derived dendritic cells from breast cancer patients are biased to induce CD4\u2009+\u2009CD25+Foxp3+ regulatory T cells. J Leukoc Biol. 2012;92:673\u201382.","journal-title":"J Leukoc Biol"},{"key":"1828_CR73","doi-asserted-by":"publisher","unstructured":"Alshetaiwi H, Pervolarakis N, McIntyre LL, Ma D, Nguyen Q, Rath JA, et al. Defining the emergence of myeloid-derived suppressor cells in breast cancer using single-cell transcriptomics. Sci Immunol. 2020. https:\/\/doi.org\/10.1126\/SCIIMMUNOL.AAY6017\/SUPPL_FILE\/AAY6017_TABLE_S9.XLSX.","DOI":"10.1126\/SCIIMMUNOL.AAY6017\/SUPPL_FILE\/AAY6017_TABLE_S9.XLSX"},{"key":"1828_CR74","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1016\/j.immuni.2016.02.025","volume":"44","author":"B Mlecnik","year":"2016","unstructured":"Mlecnik B, Bindea G, Angell HK, Maby P, Angelova M, Tougeron D, et al. Integrative analyses of colorectal cancer show immunoscore is a stronger predictor of patient survival than microsatellite instability. Immunity. 2016;44:698\u2013711.","journal-title":"Immunity"},{"key":"1828_CR75","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/j.immuni.2021.04.004","volume":"54","author":"S Hegde","year":"2021","unstructured":"Hegde S, Leader AM, Merad M. MDSC: markers, development, states, and unaddressed complexity. Immunity. 2021;54:875\u201384.","journal-title":"Immunity"},{"key":"1828_CR76","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.smim.2017.12.004","volume":"35","author":"J Zhou","year":"2018","unstructured":"Zhou J, Nefedova Y, Lei A, Gabrilovich D. Neutrophils and PMN-MDSC: their biological role and interaction with stromal cells. Semin Immunol. 2018;35:19\u201328.","journal-title":"Semin Immunol"},{"key":"1828_CR77","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1158\/1078-0432.CCR-13-2830","volume":"20","author":"MG Anitei","year":"2014","unstructured":"Anitei MG, Zeitoun G, Mlecnik B, Marliot F, Haicheur N, Todosi AM, et al. Prognostic and predictive values of the immunoscore in patients with rectal cancer. Clin Cancer Res. 2014;20:1891\u20139.","journal-title":"Clin Cancer Res"},{"key":"1828_CR78","first-page":"8820","volume":"10","author":"Z Wang","year":"2017","unstructured":"Wang Z, Zhao J, Zhao H, Sileng A, Liu Z, Zhang Y, et al. Infiltrating CD4\/CD8 high T cells shows good prognostic impact in pancreatic cancer. Int J Clin Exp Pathol. 2017;10:8820\u20138.","journal-title":"Int J Clin Exp Pathol"},{"key":"1828_CR79","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/sj.bjc.6602934","volume":"94","author":"K Hiraoka","year":"2006","unstructured":"Hiraoka K, Miyamoto M, Cho Y, Suzuoki M, Oshikiri T, Nakakubo Y, et al. Concurrent infiltration by CD8\u2009+\u2009T cells and CD4\u2009+\u2009T cells is a favourable prognostic factor in non-small-cell lung carcinoma. Br J Cancer. 2006;94:275\u201380.","journal-title":"Br J Cancer"},{"key":"1828_CR80","doi-asserted-by":"publisher","first-page":"737311","DOI":"10.3389\/fimmu.2021.737311","volume":"12","author":"H Baysal","year":"2021","unstructured":"Baysal H, De Pauw I, Zaryouh H, Peeters M, Vermorken JB, Lardon F, et al. The right partner in crime: unlocking the potential of the anti-EGFR antibody cetuximab via combination with natural killer cell chartering immunotherapeutic strategies. Front Immunol. 2021;12:737311.","journal-title":"Front Immunol"},{"key":"1828_CR81","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.3389\/fimmu.2020.01371","volume":"11","author":"Y Yang","year":"2020","unstructured":"Yang Y, Li C, Liu T, Dai X, Bazhin AV. Myeloid-derived suppressor cells in tumors: from mechanisms to antigen specificity and microenvironmental regulation. Front Immunol. 2020;11:1371.","journal-title":"Front Immunol"},{"key":"1828_CR82","doi-asserted-by":"publisher","unstructured":"Piffk\u00f3 A, Yang K, Panda A, Heide J, Tesak K, Wen C, et al. Radiation-induced amphiregulin drives tumour metastasis. Nature. 2025. https:\/\/doi.org\/10.1038\/s41586-025-08994-0.","DOI":"10.1038\/s41586-025-08994-0"},{"key":"1828_CR83","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-025-59393-y","volume":"16","author":"Y Pan","year":"2025","unstructured":"Pan Y, Cao S, Wang Y, Tang J, Niu A, Kar SA, et al. Myeloid EGFR deficiency accelerates recovery from AKI via macrophage efferocytosis and neutrophil apoptosis. Nat Commun. 2025;16:1\u201319.","journal-title":"Nat Commun"},{"key":"1828_CR84","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1161\/ATVBAHA.117.309927","volume":"38","author":"L Zeboudj","year":"2018","unstructured":"Zeboudj L, Giraud A, Guyonnet L, Zhang Y, Laurans L, Esposito B, et al. Selective EGFR (Epidermal Growth Factor Receptor) deletion in myeloid cells limits atherosclerosis - brief report. Arterioscler Thromb Vasc Biol. 2018;38:114\u20139.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"1828_CR85","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1042\/CS20230804","volume":"137","author":"AD Okyere","year":"2023","unstructured":"Okyere AD, Nayak TK, Patwa V, Teplitsky D, McEachern E, Carter RL, et al. Myeloid cell-specific deletion of epidermal growth factor receptor aggravates acute cardiac injury. Clin Sci. 2023;137:1513\u201331.","journal-title":"Clin Sci"},{"key":"1828_CR86","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/S0140-6736(21)00228-2","volume":"397","author":"A Sezer","year":"2021","unstructured":"Sezer A, Kilickap S, G\u00fcm\u00fc\u015f M, Bondarenko I, \u00d6zg\u00fcro\u011flu M, Gogishvili M, et al. Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial. Lancet. 2021;397:592\u2013604.","journal-title":"Lancet"},{"key":"1828_CR87","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1158\/1078-0432.CCR-19-1040","volume":"26","author":"Y Liu","year":"2020","unstructured":"Liu Y, Zugazagoitia J, Ahmed FS, Henick BS, Gettinger SN, Herbst RS, et al. Immune cell PD-L1 colocalizes with macrophages and is associated with outcome in PD-1 pathway blockade therapy. Clin Cancer Res. 2020;26:970\u20137.","journal-title":"Clin Cancer Res"},{"key":"1828_CR88","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1126\/scitranslmed.aav7431","volume":"12","author":"M Mayoux","year":"2020","unstructured":"Mayoux M, Roller A, Pulko V, Sammicheli S, Chen S, Sum E, et al. Dendritic cells dictate responses to PD-L1 blockade cancer immunotherapy. Sci Transl Med. 2020;12:1\u201312.","journal-title":"Sci Transl Med"},{"key":"1828_CR89","doi-asserted-by":"publisher","first-page":"5250","DOI":"10.1158\/1078-0432.CCR-19-0114","volume":"25","author":"NJ Llosa","year":"2019","unstructured":"Llosa NJ, Luber B, Tam AJ, Smith KN, Siegel N, Awan AH, et al. Intratumoral adaptive immunosuppression and type 17 immunity in mismatch repair proficient colorectal tumors. Clin Cancer Res. 2019;25:5250\u20139.","journal-title":"Clin Cancer Res"},{"key":"1828_CR90","doi-asserted-by":"publisher","unstructured":"Selenz C, Compes A, Nill M, Borchmann S, Odenthal M, Florin A, et al. EGFR inhibition strongly modulates the tumour immune microenvironment in EGFR-driven non-small-cell lung cancer. Cancers. 2022. https:\/\/doi.org\/10.3390\/cancers14163943.","DOI":"10.3390\/cancers14163943"},{"key":"1828_CR91","doi-asserted-by":"publisher","first-page":"17081","DOI":"10.1073\/pnas.0704126104","volume":"104","author":"A Natarajan","year":"2007","unstructured":"Natarajan A, Wagner B, Sibilia M. The EGF receptor is required for efficient liver regeneration. Proc Natl Acad Sci USA. 2007;104:17081\u20136.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1828_CR92","doi-asserted-by":"publisher","unstructured":"Gurbatri CR, Radford GA, Vrbanac L, Im J, Thomas EM, Coker C, et al. Engineering tumor-colonizing E. coli Nissle 1917 for detection and treatment of colorectal neoplasia. Nat Commun. 2024. https:\/\/doi.org\/10.1038\/s41467-024-44776-4.","DOI":"10.1038\/s41467-024-44776-4"},{"key":"1828_CR93","doi-asserted-by":"publisher","DOI":"10.1016\/j.xpro.2021.100841","volume":"2","author":"LR De","year":"2021","unstructured":"De LR, Law MK. Protocol tumor dissociation of highly viable cell suspensions for single-cell omic analyses in mouse models of breast cancer single-cell omic analyses in mouse models of breast. STAR Protoc. 2021;2:100841.","journal-title":"STAR Protoc"},{"key":"1828_CR94","doi-asserted-by":"publisher","unstructured":"Harada Y. Protocol to isolate and enrich mouse splenic naive CD4\u2009+\u2009T cells for in vitro CD4\u2009+\u2009CD8 aa + cell induction. STAR Protoc. 2022. https:\/\/doi.org\/10.1016\/j.xpro.2022.101728.","DOI":"10.1016\/j.xpro.2022.101728"},{"key":"1828_CR95","doi-asserted-by":"publisher","unstructured":"Wang G, Lu X, Dey P, Deng P, Wu CC, Jiang S, et al. Targeting YAP-dependent MDSC infiltration impairs tumor progression. https:\/\/doi.org\/10.1158\/2159-8290.CD-15-0224.","DOI":"10.1158\/2159-8290.CD-15-0224"},{"key":"1828_CR96","first-page":"728","volume":"543","author":"X Lu","year":"2017","unstructured":"Lu X, James W, Paul E, Shang X, Troncoso P, Deng P, et al. Castration-resistant prostate cancer. Nat Publ Group. 2017;543:728\u201332.","journal-title":"Nat Publ Group"},{"key":"1828_CR97","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15:1\u201321.","journal-title":"Genome Biol"},{"key":"1828_CR98","doi-asserted-by":"publisher","first-page":"6017","DOI":"10.1126\/sciimmunol.aay6017","volume":"5","author":"H Alshetaiwi","year":"2020","unstructured":"Alshetaiwi H, Pervolarakis N, McIntyre LL, Ma D, Nguyen Q, Rath JA, et al. Defining the emergence of myeloid-derived suppressor cells in breast cancer using single-cell transcriptomics. Sci Immunol. 2020;5:6017.","journal-title":"Sci Immunol"},{"key":"1828_CR99","doi-asserted-by":"publisher","unstructured":"Veglia F, Hashimoto A, Dweep H, Sanseviero E, de Leo A, Tcyganov E, et al. Analysis of classical neutrophils and polymorphonuclear myeloid-derived suppressor cells in cancer patients and tumor-bearing mice. J Exp Med. 2021. https:\/\/doi.org\/10.1084\/JEM.20201803.","DOI":"10.1084\/JEM.20201803"}],"container-title":["Cell Death &amp; Differentiation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41418-026-01828-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41418-026-01828-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41418-026-01828-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T19:02:27Z","timestamp":1786474947000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41418-026-01828-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,11]]},"references-count":99,"alternative-id":["1828"],"URL":"https:\/\/doi.org\/10.1038\/s41418-026-01828-0","relation":{},"ISSN":["1350-9047","1476-5403"],"issn-type":[{"value":"1350-9047","type":"print"},{"value":"1476-5403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,11]]},"assertion":[{"value":"9 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"All animal experiments were compliant with federal laws and guidelines of the Medical University of Vienna. Animal experimental procedures were approved by the Animal Experimental Ethics Committee of the Medical University of Vienna and the Austrian Federal Ministry of Science and Research (animal license numbers: BMBWF-66.009\/0319-V\/3b\/2019).","order":2,"name":"Ethics","label":"Ethics","group":{"name":"EthicsHeading","label":"Ethics"}}]}}